DRUG REGULATORY AUTHORITY OF PAKISTAN
DIVISION OF QUALITY ASSURANCE & LABORATORY TESTING

MEDICAL PRODUCT ALERT

DRAP ALERT NO. Nº I/S/11-26-55

DRUG PRODUCT DECLARED SUBSTANDARD BY DRUG TESTING LABORATORIES PUNJAB.

Date: 16th November, 2026

Target Audience:

- National Regulatory Field Force of DRAP and Provincial Drug Control Departments.
- Healthcare Professionals (Physicians, Pharmacists & Nurses).
- General Public.

Alert Summary:

Drug Testing Laboratories, Punjab informed that the samples of below mentioned drug products have been declared as '***Substandard/Adulterated***'.

S#	Product Name	Batch	Manufacturers	Remarks
1.	**Zeftrox Injection 500mg** Each vial contains Ceftriaxone Sodium USP equivalent to 500mg of Ceftriaxone	677	Zafa Pharmaceuticals Laboratories (Pvt.) Limited, Plot No. B-10, Block-B, S.I.T.E., North Karachi, Karachi.	The Sample is declared as "SUB-STANDARD" on the basis of Sterility Test by Drug Testing Laboratory, Faisalabad.
2.	**Davidax Injection 4mg/ml** Each ml contains: Dexamethasone Sodium Phosphate USP equivalent to Dexamethasone Phosphate 4 mg.	DDI 126	UNISON Chemical Works, 15Km, Raiwind Road, Lahore.	The sample is declared as "ADULTERATED" as per Section 3(a)(iv) of The Drug Act 1976 by Drug Testing Laboratory, Faisalabad.
3.	**Dormicum Injection 5mg/5ml** Each ampule contains: Midazolam (Ph.Eur) 5mg/5ml	47447 & 47661	Martin Dow Marker Ltd, 7, Jail Road, Quetta.	The above sample is declared as "SUB-STANDARD" on the basis of Visible Particulate Matter Drug Testing Laboratory, Lahore.

Risk Statement:

The use of these substandard and adulterated injectable products poses serious health risks, including treatment failure, severe infections, hypersensitivity reactions, and potential life-threatening complications due to lack of sterility, incorrect active ingredients, or presence of particulate matter.

Action initiated: -

The field force of DRAP and Provincial Drug Control departments have been directed to immediately conduct market surveys for detection of presence and removal of mentioned batches from the market.

DRAP, Islamabad
+92 051 9255969
gsms@dra.gov.pk

Advice for Pharmacies/Medical stores: -

All pharmacists and chemist working at distributions and pharmacies should **immediately check** their stocks and stop supplying mentioned products. The remaining stocks should be quarantined and returned to the supplier/company. Regulatory field force of all federating units (DRAP and Provincial Health Departments) should also increase surveillance in the market to ensure the effective recall of defective products(s).

Advice for Healthcare Professionals: -

DRAP requests increased vigilance within the supply chains of institutions/pharmacies/healthcare facilities likely to be affected by batches of mentioned products. Adverse reactions or quality problems experienced with the use of above mentioned product are to be reported to the National Pharmacovigilance Centre (NPC), DRAP using Adverse Event Reporting Form or online through this link. Further information of reporting problems to DRAP is available on this link.

Advice for Consumers/general public: -

Consumers should stop using products bearing the affected batch number(s) and shall contact to their physician or healthcare provider if they have experienced any problems that may be related to taking or using this drug product, and report the incident to Drug Regulatory Authority of Pakistan/ National Pharmacovigilance Centre.

Drug Regulatory Authority of Pakistan
محفوظ، موثر اور معیاری اشیائے